12 results on '"Buono, Mauro"'
Search Results
2. The evolving role of liquid biopsy in lung cancer
- Author
-
Malapelle, Umberto, Pisapia, Pasquale, Pepe, Francesco, Russo, Gianluca, Buono, Mauro, Russo, Alessandro, Gomez, Jorge, Khorshid, Ola, Mack, Philip C., Rolfo, Christian, and Troncone, Giancarlo
- Published
- 2022
- Full Text
- View/download PDF
3. Circulating tumor DNA in cancer: Predictive molecular pathology meets mathematics
- Author
-
Malapelle, Umberto, Buono, Mauro, Pisapia, Pasquale, Russo, Gianluca, Tufano, Rossella, Pepe, Francesco, Rolfo, Christian, and Troncone, Giancarlo
- Published
- 2021
- Full Text
- View/download PDF
4. Dose-Tracking Software: A Retrospective Analysis of Dosimetric Data in CT Procedures
- Author
-
Buono, Mauro, Capussela, Tiziana, Loffredo, Filomena, Di Pasquale, Maria Antonella, Serra, Marcello, and Quarto, Maria
- Published
- 2022
- Full Text
- View/download PDF
5. CARdioimaging in Lung Cancer PatiEnts Undergoing Radical RadioTherapy: CARE-RT Trial
- Author
-
Nardone, Valerio, primary, Belfiore, Maria Paola, additional, De Chiara, Marco, additional, De Marco, Giuseppina, additional, Patanè, Vittorio, additional, Balestrucci, Giovanni, additional, Buono, Mauro, additional, Salvarezza, Maria, additional, Di Guida, Gaetano, additional, D’Angiolella, Domenico, additional, Grassi, Roberta, additional, D’Onofrio, Ida, additional, Cimmino, Giovanni, additional, Della Corte, Carminia Maria, additional, Gambardella, Antonio, additional, Morgillo, Floriana, additional, Ciardiello, Fortunato, additional, Reginelli, Alfonso, additional, and Cappabianca, Salvatore, additional
- Published
- 2023
- Full Text
- View/download PDF
6. Role of Cardiac Biomarkers in Non-Small Cell Lung Cancer Patients
- Author
-
Nardone, Valerio, primary, Reginelli, Alfonso, additional, De Marco, Giuseppina, additional, Natale, Giovanni, additional, Patanè, Vittorio, additional, De Chiara, Marco, additional, Buono, Mauro, additional, Russo, Gaetano Maria, additional, Monti, Riccardo, additional, Balestrucci, Giovanni, additional, Salvarezza, Maria, additional, Di Guida, Gaetano, additional, D’Ippolito, Emma, additional, Sangiovanni, Angelo, additional, Grassi, Roberta, additional, D’Onofrio, Ida, additional, Belfiore, Maria Paola, additional, Cimmino, Giovanni, additional, Della Corte, Carminia Maria, additional, Vicidomini, Giovanni, additional, Fiorelli, Alfonso, additional, Gambardella, Antonio, additional, Morgillo, Floriana, additional, and Cappabianca, Salvatore, additional
- Published
- 2023
- Full Text
- View/download PDF
7. Magnetic Resonance Imaging Evaluation of Bone Metastases Treated with Radiotherapy in Palliative Intent: A Multicenter Prospective Study on Clinical and Instrumental Evaluation Assessment Concordance (MARTE Study).
- Author
-
Reginelli, Alfonso, Patanè, Vittorio, Urraro, Fabrizio, Russo, Anna, De Chiara, Marco, Clemente, Alfredo, Atripaldi, Umberto, Balestrucci, Giovanni, Buono, Mauro, D'ippolito, Emma, Grassi, Roberta, D'onofrio, Ida, Napolitano, Stefania, Troiani, Teresa, De Vita, Ferdinando, Ciardiello, Fortunato, Nardone, Valerio, and Cappabianca, Salvatore
- Subjects
MAGNETIC resonance imaging ,BONE metastasis ,MEDICAL personnel ,SPINAL cord compression ,MYELOSUPPRESSION - Abstract
Metastasis to bone is a common occurrence among epithelial tumors, with a high incidence rate in the Western world. As a result, bone lesions are a significant burden on the healthcare system, with a high morbidity index. These injuries are often symptomatic and can lead to functional limitations, which in turn cause reduced mobility in patients. Additionally, they can lead to secondary complications such as pathological fractures, spinal cord compression, hypercalcemia, or bone marrow suppression. The treatment of bone metastases requires collaboration between multiple healthcare professionals, including oncologists, orthopedists, neurosurgeons, physiatrists, and radiotherapists. The primary objective of this study is to evaluate the correlation between two methods used to assess local control. Specifically, the study aims to determine if a reduction in the volume of bone lesions corresponds to better symptomatic control in the clinical management of patients, and vice versa. To achieve this objective, the study evaluates morphological criteria by comparing pre- and post-radiotherapy treatment imaging using MRI and RECIST 1.1 criteria. MRI without contrast is the preferred diagnostic imaging method, due to its excellent tolerance by patients, the absence of exposure to ionizing radiation, and the avoidance of paramagnetic contrast media side effects. This imaging modality allows for accurate assessment of bone lesions. One of the secondary objectives of this study is to identify potentially useful parameters that can distinguish patients into two classes: "good" and "poor" responders to treatment, as reported by previous studies in the literature. These parameters can be evaluated from the imaging examinations by analyzing morphological changes and radiomic features on different sequences, such as T1, STIR (short tau inversion recovery), and DWI-MRI (diffusion-weighted). [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Dose-Tracking Software: A Retrospective Analysis of Dosimetric Data in CT Procedures
- Author
-
Mauro Buono, Tiziana Capussela, Filomena Loffredo, Maria Antonella Di Pasquale, Marcello Serra, Maria Quarto, Buono, Mauro, Capussela, Tiziana, Loffredo, Filomena, Di Pasquale, Maria Antonella, Serra, Marcello, and Quarto, Maria
- Subjects
Epidemiology ,Health, Toxicology and Mutagenesis ,Radiation Dosage ,Prospective Studie ,Retrospective Studie ,Reference Values ,Humans ,Reference Value ,Radiology, Nuclear Medicine and imaging ,Prospective Studies ,Tomography, X-Ray Computed ,Software ,Human ,Retrospective Studies - Abstract
The increasing use of ionizing radiation in healthcare is causing growing alarm about radiation protection of patients and the doses they receive during procedures. Radiation dose assessment for patients in radiodiagnostic procedures is the subject of interest in view of the recent Italian D.Lgs 31 July 2020, n. 101 (Decreto Legislativo 31 luglio 2020, n. 101) and one of its most important focuses is the prescription to provide patient exposure information as an integral part of the examination report. Dose monitoring systems are therefore essential for the collection of the dosimetric data. In order to analyse potential and critical issues of these software, different systems, adopted at the Antonio Cardarelli Hospital in Naples, were employed. Data extracted from the DoseWatch software (GE Healthcare) and Gray Detector (EL.CO. S.r.l. Healthcare Solutions, Italy) and relating to several protocols adopted for computed tomography (CT), were retrospectively analysed for the purpose of identifying critical issues in the data acquisition and recording phase, comparing with Italian nationwide diagnostic reference levels (DRLs), as provided for in regulatory provisions for radiation safety. Multiphase examinations were also included in this study. Once the distributions of volumetric CT Dose Index (CTDIvol) and dose-length product (DLP) were determined for each acquisition phase and total DLP (DLPtot) for each examination, the 25th, 50th and 75th percentiles were calculated for each distribution and then compared with the relevant Italian nationwide DRLs. In addition, to improve protocol optimization and dose reduction the magnitude of the CT acquisition settings chosen in each procedure was evaluated. In conclusion, these systems allow accurate analysis of radiation dose according to equipment and protocol over time. For the application of optimization measures, a constant use of the dose tracking software is required, which can be translated into actions on scan parameters and prospective data analysis.
- Published
- 2022
9. The evolving role of liquid biopsy in lung cancer
- Author
-
Umberto Malapelle, Pasquale Pisapia, Francesco Pepe, Gianluca Russo, Mauro Buono, Alessandro Russo, Jorge Gomez, Ola Khorshid, Philip C. Mack, Christian Rolfo, Giancarlo Troncone, Malapelle, Umberto, Pisapia, Pasquale, Pepe, Francesco, Russo, Gianluca, Buono, Mauro, Russo, Alessandro, Gomez, Jorge, Khorshid, Ola, Mack, Philip C, Rolfo, Christian, and Troncone, Giancarlo
- Subjects
Pulmonary and Respiratory Medicine ,Cancer Research ,Lung Neoplasms ,Liquid Biopsy ,High-Throughput Nucleotide Sequencing ,Biomarker ,ctDNA ,NSCLC ,Circulating Tumor DNA ,Oncology ,Carcinoma, Non-Small-Cell Lung ,Mutation ,Biomarkers, Tumor ,Humans - Abstract
Liquid biopsy has revolutionized the management of cancer patients. In particular, liquid biopsy-based testing has proven to be highly beneficial for identifying actionable cancer markers, especially when solid tissue biopsies are insufficient or unattainable. Beyond the predictive role, liquid biopsy may be a useful tool for comprehensive tumor genotyping, identification of emergent resistance mechanisms, monitoring of minimal residual disease, early detection, and cancer interception. The application of next generation sequencing to liquid biopsy has led to the "quantum leap" of predictive molecular pathology. Here, we review the evolving role of liquid biopsy in lung cancer.
- Published
- 2022
10. CARdioimaging in Lung Cancer PatiEnts Undergoing Radical RadioTherapy: CARE-RT Trial
- Author
-
Valerio Nardone, Maria Paola Belfiore, Marco De Chiara, Giuseppina De Marco, Vittorio Patanè, Giovanni Balestrucci, Mauro Buono, Maria Salvarezza, Gaetano Di Guida, Domenico D’Angiolella, Roberta Grassi, Ida D’Onofrio, Giovanni Cimmino, Carminia Maria Della Corte, Antonio Gambardella, Floriana Morgillo, Fortunato Ciardiello, Alfonso Reginelli, Salvatore Cappabianca, Nardone, Valerio, Belfiore, Maria Paola, DE CHIARA, Marco, DE MARCO, Giuseppina, Patanè, Vittorio, Balestrucci, Giovanni, Buono, Mauro, Salvarezza, Maria, Di Guida, Gaetano, D’Angiolella, Domenico, Grassi, Roberta, D’Onofrio, Ida, Cimmino, Giovanni, DELLA CORTE, Carminia Maria, Gambardella, Antonio, Morgillo, Floriana, Ciardiello, Fortunato, Reginelli, Alfonso, and Cappabianca, Salvatore
- Subjects
thoracic imaging ,Clinical Biochemistry ,cardiac MRI ,cardiac CT ,NSCLC ,radiotherapy - Abstract
Background: Non-small-cell lung cancer (NSCLC) is a common, steady growing lung tumour that is often discovered when a surgical approach is forbidden. For locally advanced inoperable NSCLC, the clinical approach consists of a combination of chemotherapy and radiotherapy, eventually followed by adjuvant immunotherapy, a treatment that is useful but may cause several mild and severe adverse effect. Chest radiotherapy, specifically, may affect the heart and coronary artery, impairing heart function and causing pathologic changes in myocardial tissues. The aim of this study is to evaluate the damage coming from these therapies with the aid of cardiac imaging. Methods: This is a single-centre, prospective clinical trial. Patients with NSCLC who are enrolled will undergo computed tomography (CT) and magnetic resonance imaging (MRI) before chemotherapy 3 months, 6 months, and 9–12 months after the treatment. We expect to enrol 30 patients in 2 years. Conclusions: Our clinical trial will be an opportunity not only to highlight the timing and the radiation dose needed for pathological cardiac tissue changes to happen but will also provide useful data to set new follow-up schedules and strategies, keeping in mind that, more often than not, patients affected by NSCLC may present other heart- and lung-related pathological conditions.
- Published
- 2023
11. Role of Cardiac Biomarkers in Non-Small Cell Lung Cancer Patients
- Author
-
Valerio Nardone, Alfonso Reginelli, Giuseppina De Marco, Giovanni Natale, Vittorio Patanè, Marco De Chiara, Mauro Buono, Gaetano Maria Russo, Riccardo Monti, Giovanni Balestrucci, Maria Salvarezza, Gaetano Di Guida, Emma D’Ippolito, Angelo Sangiovanni, Roberta Grassi, Ida D’Onofrio, Maria Paola Belfiore, Giovanni Cimmino, Carminia Maria Della Corte, Giovanni Vicidomini, Alfonso Fiorelli, Antonio Gambardella, Floriana Morgillo, Salvatore Cappabianca, Nardone, Valerio, Reginelli, Alfonso, De Marco, Giuseppina, Natale, Giovanni, Patanè, Vittorio, De Chiara, Marco, Buono, Mauro, Maria Russo, Gaetano, Monti, Riccardo, Balestrucci, Giovanni, Salvarezza, Maria, Di Guida, Gaetano, D’Ippolito, Emma, Sangiovanni, Angelo, Grassi, Roberta, D’Onofrio, Ida, Belfiore, Maria Paola, Cimmino, Giovanni, DELLA CORTE, Carminia Maria, Vicidomini, Giovanni, Fiorelli, Alfonso, Gambardella, Antonio, Morgillo, Floriana, and Cappabianca, Salvatore
- Subjects
cardio-oncology ,Clinical Biochemistry ,biomarkers ,heart ,NSCLC ,radiotherapy - Abstract
Treatment-induced cardiac toxicity represents an important issue in non-small cell lung cancer (NSCLC) patients, and no biomarkers are currently available in clinical practice. A novel and easy-to-calculate marker is the quantitative analysis of calcium plaque in the coronary, calculated on CT. It is called the Agatston score (or CAD score). At the same time, other potential predictors include cardiac ultrasonography and anamnesis of the patients. Our work aimed to correlate cardiac biomarkers with overall survival (OS) in NSCLC patients. We retrospectively analyzed patients with NSCLC discussed in the Multidisciplinary Tumor Board of our Institute for the present analysis between January 2018 and July 2022. Inclusion criteria were the availability of basal CT imaging of the thorax, cardiac ultrasonography with the calculation of ejection fraction (EF), and complete anamnesis, including assessment of co-pathologies and pharmacological drugs. The clinical data of the patients were retrospectively collected, and the CAD scores was calculated on a CT scan. All of these parameters were correlated with overall survival (OS) with univariate analysis (Kaplan–Meier analysis) and multivariate analysis (Cox regression analysis). Following the above-mentioned inclusion criteria, 173 patients were included in the present analysis. Of those, 120 patients died in the follow-up period (69.6%), and the median overall survival (OS) was 28 months (mean 47.2 months, 95% CI, 36–57 months). In univariate analysis, several parameters that significantly correlated with lower OS were the stage (p < 0.001), the CAD grading (p < 0.001), history of ischemic heart disease (p: 0.034), use of beta blocker drugs (p: 0.036), and cardiac ejection fraction (p: 0.005). In multivariate analysis, the only parameters that remained significant were as follows: CAD score (p: 0.014, OR 1.56, 95% CI: 1.04–1.83), stage (p: 0.016, OR: 1.26, 95% CI: 1.05–1.53), and cardiac ejection fraction (p: 0.011, OR 0.46, 95% CI: 0.25–0.84). Both CAD score and ejection fraction are correlated with survival in NSCLC patients at all stages of the disease. Independently from the treatment choice, a cardiological evaluation is mandatory for patients with NSCLC.
- Published
- 2023
12. Circulating tumor DNA in cancer: Predictive molecular pathology meets mathematics
- Author
-
Giancarlo Troncone, Mauro Buono, Pasquale Pisapia, Christian Rolfo, Umberto Malapelle, Gianluca Russo, Rossella Tufano, Francesco Pepe, Malapelle, Umberto, Buono, Mauro, Pisapia, Pasquale, Russo, Gianluca, Tufano, Rossella, Pepe, Francesco, Rolfo, Christian, and Troncone, Giancarlo
- Subjects
0301 basic medicine ,Computational biology ,DNA sequencing ,Circulating Tumor DNA ,03 medical and health sciences ,0302 clinical medicine ,Circulating tumor cell ,Neoplasms ,Biomarkers, Tumor ,Humans ,Medicine ,Pathology, Molecular ,Allele ,Liquid biopsy ,Molecular pathology ,business.industry ,High-Throughput Nucleotide Sequencing ,Cancer ,Hematology ,medicine.disease ,030104 developmental biology ,Oncology ,Cell-free fetal DNA ,030220 oncology & carcinogenesis ,Mutation ,Cancer biomarkers ,business ,Mathematics - Abstract
The cancer secretome is a valuable reservoir of cancer biomarkers. Besides containing circulating tumor cells, extracellular vesicles, and proteins, it is also rich in circulating tumor DNA (ctDNA)-a subpopulation of cell free DNA. The most efficient technology to capture ctDNA is next generation sequencing (NGS). Indeed, this analysis enables the identification of both quantitative (e.g., mutant allelic fraction - MAF) and qualitative (e.g., the variant type) information. Strikingly, by calculating these data in relation to time, cytopathologists can decodify and graphically report the ctDNA "message", which may help to diagnose cancer, define treatment, and monitor disease evolution. In this paper, we report the most compelling evidence steadily accumulating on the successful application of NGS-based ctDNA analysis in cancer diagnosis, treatment decision, and monitoring of cancer progression. We also propose a mathematical model that calculates MAF evolution in relation to time.
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.